MX344621B - Analisis dimensional de conjugados sacaridos con cromatografia de permeacion en gel y cromatografia de exclusion de tamaño con deteccion mediante fotometria de dispersion de luz de angulos multiples. - Google Patents

Analisis dimensional de conjugados sacaridos con cromatografia de permeacion en gel y cromatografia de exclusion de tamaño con deteccion mediante fotometria de dispersion de luz de angulos multiples.

Info

Publication number
MX344621B
MX344621B MX2011011568A MX2011011568A MX344621B MX 344621 B MX344621 B MX 344621B MX 2011011568 A MX2011011568 A MX 2011011568A MX 2011011568 A MX2011011568 A MX 2011011568A MX 344621 B MX344621 B MX 344621B
Authority
MX
Mexico
Prior art keywords
mals
gpc
sec
sample
saccharide conjugates
Prior art date
Application number
MX2011011568A
Other languages
English (en)
Inventor
Capannoli Giorgio
Carinci Valeria
D'ascenzi Sandro
Magagnoli Claudia
Original Assignee
Novartis Vaccines And Diagnostics S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines And Diagnostics S R L filed Critical Novartis Vaccines And Diagnostics S R L
Publication of MX344621B publication Critical patent/MX344621B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Spectrometry And Color Measurement (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)

Abstract

La presente invención se refiere a una composición caracterizada porque comprende: un conjugado de un sacárido capsular del serogrupo A de N.meningitis, en donde el tamaño molecular del conjugado es de 5.71% ± 2% nm (57.1 ± 2% A) y la masa molar del conjugado es de 99.5 ± 2% kDa, un conjugado de un sacárido capsular del serogrupo Cde N, meningitidis, en donde el tamaño molecular del conjugado es de 5.70% ± 2% nm (57.9 ± 2% A) y la masa molar del conjugado es de 85.2 ± 2% kDa, un conjugado de un sacárido capsular del serogrupo W 135 de N. meningitidis, en donde el tamaño molecular del conjugado es de 6.87 ± 2% A) y la masa molar del conjugado es de 110.1 ± 2% kDa y un conjugado es de 110.1 ± 2% kDa y un conjugado de un sacárido capsular del serogrupo Y de N. meningitidis, en donde el tamaño molecular del conjugado es de 6.33 ± 2% nm (63.3 2% A) y la masa molar del conjugado es de 84.7 ± 2% kDa, en donde el vehiculo de proteína para cada conjugado es CRM 197.
MX2011011568A 2004-06-21 2006-12-20 Analisis dimensional de conjugados sacaridos con cromatografia de permeacion en gel y cromatografia de exclusion de tamaño con deteccion mediante fotometria de dispersion de luz de angulos multiples. MX344621B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0413868.1A GB0413868D0 (en) 2004-06-21 2004-06-21 Dimensional anlaysis of saccharide conjugates

Publications (1)

Publication Number Publication Date
MX344621B true MX344621B (es) 2017-01-03

Family

ID=32750313

Family Applications (2)

Application Number Title Priority Date Filing Date
MXPA06015188A MXPA06015188A (es) 2004-06-21 2005-06-21 Analisis dimensional de conjugados sacaridos con cromatrografia de permeacion en gel y cromatografia de exclusion de tamano con deteccion mediante fotometria de dispersion de luz de angulos multiples.
MX2011011568A MX344621B (es) 2004-06-21 2006-12-20 Analisis dimensional de conjugados sacaridos con cromatografia de permeacion en gel y cromatografia de exclusion de tamaño con deteccion mediante fotometria de dispersion de luz de angulos multiples.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MXPA06015188A MXPA06015188A (es) 2004-06-21 2005-06-21 Analisis dimensional de conjugados sacaridos con cromatrografia de permeacion en gel y cromatografia de exclusion de tamano con deteccion mediante fotometria de dispersion de luz de angulos multiples.

Country Status (13)

Country Link
US (2) US8163296B2 (es)
EP (2) EP2374473B1 (es)
JP (5) JP2008503716A (es)
CN (1) CN1976725B (es)
AU (1) AU2005256961B2 (es)
BR (1) BRPI0512281A (es)
CA (1) CA2571565C (es)
ES (2) ES2443465T3 (es)
GB (1) GB0413868D0 (es)
MX (2) MXPA06015188A (es)
NZ (1) NZ552449A (es)
RU (1) RU2422156C2 (es)
WO (1) WO2006000920A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0413868D0 (en) * 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
PT1896065E (pt) 2005-06-27 2011-08-31 Glaxosmithkline Biolog Sa Processo para a preparação de vacinas
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
TW201009337A (en) 2008-05-30 2010-03-01 Intervet Int Bv Analytical method to monitor vaccine potency and stability
EP2437882A4 (en) 2009-06-01 2016-11-23 Waters Technologies Corp HYBRID MATERIAL FOR CHROMATOGRAPHY SEPARATIONS
WO2012018596A2 (en) 2010-07-26 2012-02-09 Waters Technologies Corporation Superficially porous materials comprising a substantially nonporous hybrid core having narrow particle size distribution; process for the preparation thereof; and use thereof for chromatographic separations
US8195405B2 (en) * 2009-06-30 2012-06-05 Wyatt Technology Corporation Method for characterizing reversible association of macromolecules at high concentration
MX2012004851A (es) * 2009-10-30 2012-05-22 Novartis Ag Purificacion de sacaridos capsulares de staphylococcus aureus tipo 5 y tipo 8.
EP4023330A1 (en) * 2009-12-15 2022-07-06 Waters Technologies Corporation Device and methods for performing size exclusion chromatography
EP2575773A4 (en) * 2010-05-26 2014-06-25 Selecta Biosciences Inc SYNTHETIC NANOTRÄGERKOMBINATIONSIMPFSTOFFE
AU2011294776B2 (en) 2010-08-23 2016-02-04 Wyeth Llc Stable formulations of Neisseria meningitidis rLP2086 antigens
CA2809758C (en) 2010-09-10 2021-07-13 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
EP4043029A1 (en) 2012-03-09 2022-08-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US10481164B2 (en) 2012-03-26 2019-11-19 Amgen Inc. Method for using light scattering in real time to directly monitor and control impurity removal in purification processes
ES2685894T3 (es) 2013-03-08 2018-10-15 Pfizer Inc. Polipéptidos de fusión inmunogénicos
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
RU2723045C2 (ru) 2015-02-19 2020-06-08 Пфайзер Инк. Композиции neisseria meningitidis и способы их получения
EP4309670A3 (en) 2016-09-02 2024-07-17 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
CN118662649A (zh) 2016-12-30 2024-09-20 Vaxcyte公司 具有非天然氨基酸的多肽-抗原缀合物
MX2019009011A (es) 2017-01-31 2019-09-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos.
CN109459504B (zh) * 2017-09-06 2022-05-27 绿谷(上海)医药科技有限公司 一种测定聚古罗糖醛酸硫酸酯盐重均分子量和含量的方法
CN109459523B (zh) * 2017-09-06 2022-11-08 上海绿谷制药有限公司 一种测定酸性糖可溶性盐重均分子量和含量的方法
JP7409055B2 (ja) * 2019-12-05 2024-01-09 株式会社島津製作所 検出器の出力を補正する方法、および多角度光散乱検出器

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
JPH01125328A (ja) 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
WO1991001146A1 (en) 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
ATE128628T1 (de) 1990-08-13 1995-10-15 American Cyanamid Co Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
ATE400295T1 (de) 1995-06-07 2008-07-15 Glaxosmithkline Biolog Sa Vakzine mit einem polysaccharide antigen- trägerprotein konjugat und freiem trägerprotein
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
DE69941574D1 (de) 1998-08-19 2009-12-03 Baxter Healthcare Sa Immunogenes beta-propionamido-gebundenes polysaccharid-protein konjugat geeignet als impfstoff und hergestellt bei verwendung von n-acryloyliertem polysaccharid
HU228499B1 (en) 1999-03-19 2013-03-28 Smithkline Beecham Biolog Streptococcus vaccine
AU781027B2 (en) 1999-04-09 2005-04-28 Department Of Health & Human Services Recombinant toxin a protein carrier for polysaccharide conjugate vaccines
DK1897555T3 (da) 2000-01-17 2014-10-13 Novartis Vaccines & Diagnostic Kompletteret OMV-vaccine mod meningococcus
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
US6936261B2 (en) 2000-07-27 2005-08-30 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
HU230490B1 (hu) * 2001-01-23 2016-08-29 Sanofi Pasteur Inc. Multivalens, meningokokkusz-eredetű poliszaccharid és fehérje konjugátumát tartalmazó vakcina
AU2002309706A1 (en) * 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
HUE031886T2 (en) * 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
CA2514328C (en) 2003-01-30 2020-01-14 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
EP1670506B1 (en) * 2003-10-02 2012-11-21 Novartis AG Liquid vaccines for multiple meningococcal serogroups
GB0408978D0 (en) 2004-04-22 2004-05-26 Chiron Srl Meningococcal fermentation for preparing conjugate vaccines
GB0413868D0 (en) * 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates

Also Published As

Publication number Publication date
AU2005256961B2 (en) 2011-06-23
US8163296B2 (en) 2012-04-24
GB0413868D0 (en) 2004-07-21
US20080248059A1 (en) 2008-10-09
JP2017134084A (ja) 2017-08-03
JP2008503716A (ja) 2008-02-07
JP2014111654A (ja) 2014-06-19
JP6218327B2 (ja) 2017-10-25
CA2571565A1 (en) 2006-01-05
MXPA06015188A (es) 2007-03-27
EP2374473B1 (en) 2018-07-18
US20120207781A1 (en) 2012-08-16
NZ552449A (en) 2010-05-28
CN1976725B (zh) 2012-08-29
JP2011246490A (ja) 2011-12-08
EP2374473A1 (en) 2011-10-12
BRPI0512281A (pt) 2008-02-26
RU2007102016A (ru) 2008-07-27
JP2015180707A (ja) 2015-10-15
CN1976725A (zh) 2007-06-06
AU2005256961A1 (en) 2006-01-05
CA2571565C (en) 2014-08-12
WO2006000920A3 (en) 2006-03-30
WO2006000920A2 (en) 2006-01-05
ES2443465T3 (es) 2014-02-19
EP1778291B1 (en) 2013-10-30
RU2422156C2 (ru) 2011-06-27
ES2688796T3 (es) 2018-11-07
EP1778291A2 (en) 2007-05-02
JP6661568B2 (ja) 2020-03-11

Similar Documents

Publication Publication Date Title
MX344621B (es) Analisis dimensional de conjugados sacaridos con cromatografia de permeacion en gel y cromatografia de exclusion de tamaño con deteccion mediante fotometria de dispersion de luz de angulos multiples.
WO2006113476A3 (en) Non-invasive system for measuring glucose in the body
GB2449043A (en) Water soluble conjugates for electrochemical detection
WO2009117033A3 (en) Scanning analyzer for single molecule detection and methods of use
NZ590930A (en) Improving the calibration accuracy of a fluidic system by comparing test readings with a calibration curve and then adjusting the signal output
DE60228557D1 (de) Candida-nachweis
WO2005113817A3 (en) Aptamer-nanoparticle conjugates and method of use for target analyte detection
WO2002066986A3 (en) Polymers functionalized with fluorescent boronate motifs
TW200609507A (en) Antigen rapid detecting and/or measuring method by fluorescent correlation spectral method
AR054474A1 (es) Formulacion de anticuerpos estables
NO20084083L (no) Anordning og fremgangsmate for detektering av fluorescensmerkede biologiske komponenter
BRPI0509681A (pt) aparelho e método para analisar acusticamente um fluido
CA2701341A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
EP1672673A3 (en) Self-calibration of mass spectra using robust statistical methods
MX2010013692A (es) Deteccion de uso de cannabis.
WO2008096225A3 (en) Drug detection kit and method
MX2009006205A (es) Inmunoensayo de multiples analitos.
ATE447712T1 (de) Immunoassay mit doppelter standardkurve
WO2006113477A3 (en) Use of phosphonazo iii for the measurement of calcium, magnesium and sodium in analytical samples
DK1946083T3 (da) Fremgangsmåde til detektion af biologiske organismer under anvendelse af ramanspredning
WO2006004958A3 (en) Detection or measurement of antibodies to antigenic proteins in biological tissues or samples
WO2007149809A3 (en) Tacrolimus standard and methods of using same
WO2005124356A3 (en) Use of protein cbp2 as a marker for colorectal cancer
WO2009055387A8 (en) Polymerized conjugates for biological applications
TW200739073A (en) Test sensor reagent having cellulose polymers